[{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"80d8b063-fde0-450d-9857-f3e96ed43e05","acronym":"STELLAR-305","url":"https://clinicaltrials.gov/study/NCT06082167","created_at":"2023-10-14T01:13:13.670Z","updated_at":"2025-02-25T16:19:12.483Z","phase":"Phase 2/3","brief_title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06082167 - STELLAR-305","lead_sponsor":"Exelixis","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-01-31"},{"id":"f33d52c2-9a8f-4b5c-acef-4121e6304fc8","acronym":"CA209-982","url":"https://clinicaltrials.gov/study/NCT03583086","created_at":"2021-01-18T17:37:36.257Z","updated_at":"2025-02-25T14:27:15.271Z","phase":"Phase 1/2","brief_title":"Phase I/II Eval Safety \u0026 Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","source_id_and_acronym":"NCT03583086 - CA209-982","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" EGFR • PD-L1 • BRAF • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 04/27/2024","study_completion_date":" 04/27/2024","last_update_posted":"2024-10-08"},{"id":"f62d8147-2a38-4f77-b038-bf10198180d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06561620","created_at":"2025-02-27T08:10:23.102Z","updated_at":"2025-02-27T08:10:23.102Z","phase":"Phase 4","brief_title":"Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients","source_id_and_acronym":"NCT06561620","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Semena (befotertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 592","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-08-22"},{"id":"aa10c497-874a-4e78-b3a1-858e57d57b8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198650","created_at":"2021-01-18T15:46:19.909Z","updated_at":"2024-07-02T16:34:27.508Z","phase":"Phase 1","brief_title":"A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies","source_id_and_acronym":"NCT03198650","lead_sponsor":"AstraZeneca","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/27/2017","start_date":" 06/27/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-06-11"},{"id":"d8485b72-fd46-4a36-8dc8-65fce07dac67","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841723","created_at":"2021-01-18T08:12:27.496Z","updated_at":"2024-07-02T16:34:27.123Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT01841723","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/30/2013","start_date":" 04/30/2013","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-11"},{"id":"40b74cbe-0048-46ef-9bea-782d3936a358","acronym":"ASC4KIDS","url":"https://clinicaltrials.gov/study/NCT04925479","created_at":"2021-06-14T18:52:41.613Z","updated_at":"2024-07-02T16:34:36.877Z","phase":"Phase 1/2","brief_title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04925479 - ASC4KIDS","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-10"},{"id":"6f307756-0908-4621-b9f3-65923112cc09","acronym":"SHINE ","url":"https://clinicaltrials.gov/study/NCT01776840","created_at":"2021-01-18T07:50:07.776Z","updated_at":"2024-07-02T16:34:37.245Z","phase":"Phase 3","brief_title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01776840 - SHINE ","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20 • CCND1 • PAX5 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CCND1 expression","tags":["CD20 • CCND1 • PAX5 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-07"},{"id":"839f620b-12d4-4a91-a1bc-669aefdc71c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496663","created_at":"2024-03-06T21:31:26.529Z","updated_at":"2024-07-02T16:34:58.872Z","phase":"Phase 1","brief_title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT02496663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"72f7e625-8a17-4823-ab2b-fcbb2d97c51f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014464","created_at":"2021-08-20T14:52:58.520Z","updated_at":"2024-07-02T16:34:59.693Z","phase":"","brief_title":"ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma","source_id_and_acronym":"NCT05014464","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 08/08/2027","study_completion_date":" 08/08/2027","last_update_posted":"2024-05-31"},{"id":"9b677f8f-b3e7-4b6d-8718-36c028b32cda","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329325","created_at":"2022-04-24T09:02:32.988Z","updated_at":"2024-07-02T16:35:00.993Z","phase":"Phase 2","brief_title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04329325","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • dexamethasone • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-24"},{"id":"4c088dd4-b200-4ede-a7fc-cf87edb6f419","acronym":"REZILIENT2","url":"https://clinicaltrials.gov/study/NCT05967689","created_at":"2023-08-01T16:10:25.528Z","updated_at":"2024-07-02T16:35:02.952Z","phase":"Phase 2","brief_title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","source_id_and_acronym":"NCT05967689 - REZILIENT2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 10/20/2025","study_completion_date":" 10/20/2025","last_update_posted":"2024-05-17"},{"id":"d61ddbc3-bb32-4dda-8c4c-406b6f74dc87","acronym":"HARMONIC","url":"https://clinicaltrials.gov/study/NCT05456256","created_at":"2022-07-13T12:56:31.097Z","updated_at":"2024-07-02T16:35:03.235Z","phase":"Phase 2","brief_title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT05456256 - HARMONIC","lead_sponsor":"Lantern Pharma Inc.","biomarkers":" EGFR • ALK • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Pemfexy (pemetrexed) • Tavocept (dimesna)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-05-16"},{"id":"f0da2c69-063d-412e-8403-ded1fd245a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05845671","created_at":"2023-05-06T15:04:41.894Z","updated_at":"2024-07-02T16:35:04.160Z","phase":"Phase 1/2","brief_title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","source_id_and_acronym":"NCT05845671","lead_sponsor":"University of Colorado, Denver","biomarkers":" RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-05-13"},{"id":"bf879c20-915a-45bc-aa7f-bfcae5d8514b","acronym":"ASC4OPT","url":"https://clinicaltrials.gov/study/NCT04948333","created_at":"2021-07-01T14:54:54.307Z","updated_at":"2024-07-02T16:35:05.406Z","phase":"Phase 3","brief_title":"Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.","source_id_and_acronym":"NCT04948333 - ASC4OPT","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-07"},{"id":"a7d78ad7-64d9-4db4-b558-cc07349edbdc","acronym":"REZILIENT3","url":"https://clinicaltrials.gov/study/NCT05973773","created_at":"2023-08-03T15:09:38.478Z","updated_at":"2024-07-02T16:35:06.229Z","phase":"Phase 3","brief_title":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","source_id_and_acronym":"NCT05973773 - REZILIENT3","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 07/27/2026","primary_completion_date":" 07/27/2026","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2024-05-03"},{"id":"63acc23b-8534-4603-8475-20ff97145f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805631","created_at":"2023-04-10T14:03:05.133Z","updated_at":"2024-07-02T16:35:06.695Z","phase":"Phase 2","brief_title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","source_id_and_acronym":"NCT05805631","lead_sponsor":"Taipei Veterans General Hospital, Taiwan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-01"},{"id":"e6e36ef9-1a28-4271-9c2d-5395fb082dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT06390306","created_at":"2024-04-30T19:56:36.690Z","updated_at":"2024-07-02T16:35:06.686Z","phase":"","brief_title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","source_id_and_acronym":"NCT06390306","lead_sponsor":"Peking University People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"2496a405-f709-49ff-9442-cc8f42dfeb39","acronym":"RAMOSE","url":"https://clinicaltrials.gov/study/NCT03909334","created_at":"2021-01-18T19:14:34.350Z","updated_at":"2024-07-02T16:35:07.044Z","phase":"Phase 2","brief_title":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03909334 - RAMOSE","lead_sponsor":"Xiuning Le","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-30"},{"id":"0b209ec8-a98e-41ee-a425-a93147024dd7","acronym":"CLN-081-001","url":"https://clinicaltrials.gov/study/NCT04036682","created_at":"2021-01-17T17:46:54.407Z","updated_at":"2024-07-02T16:35:07.435Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04036682 - CLN-081-001","lead_sponsor":"Cullinan Therapeutics Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 10/31/2019","start_date":" 10/31/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-26"},{"id":"1cd8b8e0-c288-4356-b1d4-81c289387f1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838041","created_at":"2021-04-08T12:52:35.090Z","updated_at":"2024-07-02T16:35:11.769Z","phase":"Phase 2","brief_title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","source_id_and_acronym":"NCT04838041","lead_sponsor":"Medical College of Wisconsin","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-04-03"},{"id":"58a13adb-b09f-4fe4-9e51-f50226226a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05143840","created_at":"2021-12-03T17:53:27.865Z","updated_at":"2024-07-02T16:35:12.755Z","phase":"Phase 2","brief_title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05143840","lead_sponsor":"Augusta University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-03-26"},{"id":"173af6b1-9f89-47ec-aea7-839d167ece02","acronym":"","url":"https://clinicaltrials.gov/study/NCT05753384","created_at":"2023-03-03T15:01:37.382Z","updated_at":"2024-07-02T16:35:13.801Z","phase":"Phase 3","brief_title":"Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System","source_id_and_acronym":"NCT05753384","lead_sponsor":"Poitiers University Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-20"}]